<DOC>
	<DOCNO>NCT02791763</DOCNO>
	<brief_summary>This Phase III , open-label , active-controlled , parallel-group , multi-center study compare efficacy ( verification noninferiority ) safety GSK1278863 administer 52 week versus epoetin beta pegol approximately 270 Japanese non-dialysis ( ND ) 50 peritoneal dialysis ( PD ) subject renal anemia . The study consist 2 cohort different subject population . This study consist 4-week screen phase , 52-week treatment phase ( include primary efficacy evaluation period [ Weeks 40 52 ] ) , 4-week follow-up phase follow treatment phase . The primary objective study demonstrate non-inferiority GSK1278863 epoetin beta pegol base hemoglobin ( Hgb ) ND subject population include study . Study result use pivotal study data NDA submit GSK1278863 treatment renal anemia Japan .</brief_summary>
	<brief_title>Phase III Study GSK1278863 Japanese Non-dialysis Peritoneal Dialysis Subjects With Renal Anemia</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Epoetin Alfa</mesh_term>
	<mesh_term>Glycine</mesh_term>
	<criteria>Age ( informed consent ) : &gt; =20 year age Stage chronic kidney disease ( CKD ) ( ND subject ) : CKD stage 3 , 4 , 5 define estimate glomerular filtration rate ( eGFR ) use Japanese Society NephrologyChronic Kidney Disease Initiatives ( JSNCKDI ) formula Dialysis : Not dialysis least 12 week prior screen ( ND subject ) On peritoneal dialysis ( PD subject ) Use erythropoiesisstimulating agent ( ESA ) : ESA nonusers : Have use ESAs 8 week prior screen ESA user : Have use ESA 8 week prior screen . However , ND subject , dose darbepoetin alfa epoetin beta pegol must stable ( administer every 4 week onestep dose change 8 week prior screen ) . Hemoglobin ( Hgb ) : Determined site use Hgb analyzer ESA nonusers : &gt; =8.0 g/dL &lt; 11.0 g/dL ESA user : &gt; =9.0 g/dL &lt; =13.0 g/dL Iron parameter : Ferritin &gt; 100 nanogram per millilitre ( ng/mL ) transferrin saturation ( TSAT ) &gt; 20 % ( screen verification ) Gender ( screen verification ) : Female male . Females : Not pregnant [ demonstrate negative human chorionic gonadotropin ( hCG ) urine serum ] , breastfeeding , meet least one following : 1 . Females nonchildbearing potential defined follow : Premenopausal least one follow plan utilise assist reproductive technique ( e.g. , vitro fertilisation donor embryo transfer ) : History bilateral tubal ligation salpingectomy History hysteroscopic tubal occlusion postoperatively document bilateral tubal obstruction History hysterectomy History bilateral oophorectomy Postmenopausal define : female 60 year age old ; In female &lt; 60 year age , 12 month spontaneous amenorrhea ( questionable case blood sample postmenopausal follicle stimulate hormone [ FSH ] estradiol concentration confirmatory [ specify reference range ] ) . Females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one effective contraception method wish continue HRT study . Otherwise must discontinue HRT allow confirmation postmenopausal status prior study enrolment . 2 . Females childbearing potential must agree comply one contraception method list requirement `` GSK Listing Most Effective Contraceptive Methods Females Childbearing Potential '' 28 day prior first dose study medication completion followup visit ( subject randomize GSK1278863 group ) 7 week last dose study treatment ( subject randomize Epoetin beta pegol group ) . Informed consent : Written inform consent , include adherence requirement condition specify consent form protocol , must obtain subject specify Protocol . Chronic kidney disease ( CKD ) relate criteria Dialysis Cohort 1 : Start plan initiate dialysis study Cohort 2 : Plan stop peritoneal dialysis start hemodialysis study Kidney transplant : Planned livingrelated kidney transplant study Anemiarelated criterion Aplasia : History bonemarrow hypoplasia pure red cell aplasia Other cause anemia : pernicious anemia , thalassemia , sickle cell anemia , myelodysplastic syndrome Gastrointestinal ( GI ) bleeding : Evidence actively bleed gastric , duodenal , esophageal ulcer disease OR clinically significant GI bleeding within 8 week prior screen period screen Day 1 . Cardiovascular diseaserelated criterion Myocardial infarction , acute coronary syndrome , stroke , transient ischemic attack : Diagnosed within 8 week prior screen period screen Day 1 . Heart failure : Class IV heart failure , define New York Heart Association ( NYHA ) functional classification system QTc ( screen verification ) : QTc &gt; 500 msec QTc &gt; 530 msec subject bundle branch block Note : QT interval correct use Bazett 's formula ( QTcB ) use , Electrocardiogram ( ECG ) mechanically manually read . Other diseaserelated criterion Liver disease ( follow occurs ) : Alanine transaminase ( ALT ) &gt; 2×upper limit normal ( ULN ) Bilirubin &gt; 1.5×ULN ( isolated bilirubin &gt; 1.5×ULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) Current unstable active liver biliary disease ( generally define onset ascites , encephalopathy , coagulopathy , hypoalbuminemia , esophageal/gastric varix , persistent jaundice , cirrhosis ) Note : Stable liver disease ( include asymptomatic gallstone , chronic hepatitis B/C , Gilbert 's syndrome ) acceptable subject otherwise meet entry criteria.. Malignancy : History malignancy within 2 year prior screen , currently receive treatment cancer , ( PD subject ) complex renal cystic &gt; 3 centimeter ( cm ) ( II F , III IV base Bosniak classification ) Note ( ND subject PD subject ) : The exception squamous cell basal cell carcinoma skin definitively treat &gt; =8 week screen . In opinion investigator , Hgb increase target range ( 11.013.0 g/dL ) medically risky . Concomitant medication study treatmentrelated criterion Iron : Planned use intravenous iron screen phase period Day 1 Week 4 Note : Oral iron acceptable . However , dose regimen must use throughout screen phase Day 1 Week 4 . Antihyperphosphatemic agent contain iron ( e.g. , ferric citrate hydrate ) also acceptable use least 12 week prior screen . However , must continue throughout screen phase Day 1 Week 4 . Severe allergic reaction : History severe allergic anaphylactic reaction hypersensitivity excipients investigational product epoetin beta pegol Drugs supplement : Use plan use prescription nonprescription drug dietary supplement prohibit study period ( prohibited medication : strong inducer inhibitor Cytochrome P450 2C8 [ CYP2C8 ] ) Prior investigational product exposure : Use investigational agent within 30 day five half live investigational agent ( whichever longer ) Prior treatment GSK1278863 : Any prior treatment GSK1278863 treatment duration &gt; 30 day General healthrelated criterion Other condition : Any condition , clinical laboratory abnormality , examination find investigator ( subinvestigator ) considers would put subject unacceptable risk , may affect study compliance prevent understand aim investigational procedure possible consequence study .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Renal Anemia</keyword>
	<keyword>Japanese</keyword>
	<keyword>chronic kidney disease</keyword>
	<keyword>Peritoneal dialysis</keyword>
	<keyword>GSK1278863</keyword>
	<keyword>Non-dialysis</keyword>
</DOC>